Literature DB >> 3194671

Epidemiological studies of onchocerciasis in forest villages of Sierra Leone.

J E McMahon1, S C Sowa, G H Maude, C M Hudson, B R Kirkwood.   

Abstract

Results are presented for five villages in the forest zone of Sierra Leone in which forest onchocerciasis was considered to be a significant health problem. All five villages were found to be hyperendemic and 85% (682/803) of persons were found to have at least one sign of onchocerciasis. The emergence of microfilariae from skin snips (iliac crest and/or canthus) or the presence of nodules accounted for 96.5% of all persons positive for onchocerciasis. The prevalence of nodules from all body sites was 70.5% and of elephantiasis, hanging groin and skin lesions (moderate and severe) was 0.4%, 0.3% and 5.3% respectively. Analysis of eye lesions (the most serious clinical manifestation of the disease) was restricted to persons aged 30 years and over since this gives a better indication of the public health importance of onchocerciasis than analysis in the overall population. This gave prevalence rates of onchocercal blindness of 4.5% (both eyes) and 2.8% (one eye only). Rates for the four potentially blinding eye lesions were sclerosing keratitis (4.1%), iritis (16.5%), optic atrophy (13.8%) and choroidoretinitis (14.4%). Rates in males were approximately twice as high as those in females.

Entities:  

Mesh:

Year:  1988        PMID: 3194671

Source DB:  PubMed          Journal:  Trop Med Parasitol        ISSN: 0177-2392


  2 in total

1.  Hyperendemicity of onchocerciasis in ovia northeast local government area, edo state, Nigeria.

Authors:  Frederick Olusegun Akinbo; Christopher Ehis Okaka
Journal:  Malays J Med Sci       Date:  2010-10

2.  Impact of five annual rounds of mass drug administration with ivermectin on onchocerciasis in Sierra Leone.

Authors:  Joseph B Koroma; Santigie Sesay; Abdul Conteh; Benjamin Koudou; Jusufu Paye; Mohamed Bah; Mustapha Sonnie; Mary H Hodges; Yaobi Zhang; Moses J Bockarie
Journal:  Infect Dis Poverty       Date:  2018-04-06       Impact factor: 4.520

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.